4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-26-207148
Chief Operating Officer sold 4,750 shares at an average $227.95 ($1,082,771)
- Chief Operating Officer acquired 4,750 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. Chief Operating Officer | 2026-05-04 | Option exercise 10b5-1 | +4,517 | $12.95 | $58,495 | 4,517 | D |
| Jacobson Mark L. Chief Operating Officer | 2026-05-04 | Sale 10b5-1 | −4,517 | $227.94 | $1,029,605 | 0 | D |
| Jacobson Mark L. Chief Operating Officer | 2026-05-05 | Option exercise 10b5-1 | +233 | $12.95 | $3,017 | 233 | D |
| Jacobson Mark L. Chief Operating Officer | 2026-05-05 | Sale 10b5-1 | −233 | $228.18 | $53,166 | 0 | D |
| Derivatives | |||||||
| Jacobson Mark L. Chief Operating Officer | 2026-05-04 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,517 | 115,187 | D | ||
| Jacobson Mark L. Chief Operating Officer | 2026-05-05 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −233 | 114,954 | D | ||
| Open-market sales · 4,750 sh · avg $227.95 · $1,082,771 | |||||||
Loading xslF345X06/ownership.xml…